AVROBIO Inc

NASDAQ AVRO

Download Data

AVROBIO Inc Return on Net Assets (RONA) 2 year CAGR for the year ending December 31, 2023

AVROBIO Inc Return on Net Assets (RONA) 2 year CAGR is NA for the year ending December 31, 2023. Return on net assets measures the profitability of a company relative to its net assets, which include total non-current assets and working capital. It is calculated by dividing the net income by the sum of total non-current assets and working capital. This ratio indicates the return generated for each unit of net asset investment made by the company. A higher return on net assets suggests better profitability and efficient utilization of the company's asset base. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • AVROBIO Inc Return on Net Assets (RONA) for the year ending December 31, 2022 was -55.37%, a -80.43% change year over year.
  • AVROBIO Inc Return on Net Assets (RONA) for the year ending December 31, 2021 was -30.69%, a -35.15% change year over year.
  • AVROBIO Inc Return on Net Assets (RONA) for the year ending December 31, 2020 was -22.71%, a -20.35% change year over year.
  • AVROBIO Inc Return on Net Assets (RONA) for the year ending December 31, 2019 was -18.87%, a -2.93% change year over year.
NASDAQ: AVRO

AVROBIO Inc

CEO Mr. Geoff MacKay BSc
IPO Date June 21, 2018
Location United States
Headquarters Building 300, Cambridge, MA, United States, 02139
Employees 13
Sector Healthcare
Industry Biotechnology
Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email